ClinicalTrials.gg
RecruitingNCT03860883MelMarT-IIUpdated Nov 27, 2024

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

An interventional study of Wide Local Excision = 1cm Margin and Wide Local Excision = 2cm Margin in Cutaneous Melanoma, Stage II, sponsored by Melanoma and Skin Cancer Trials Limited. Recruiting at 192 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by Melanoma and Skin Cancer Trials Limited · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,998
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Melanoma by Melanoma and Skin Cancer Trials Limited — 2 open to participants now, 4 under way, none of them phase 3. Melanoma · Melanoma and Skin Cancer Trials Limited.

Planned enrollment
Largest of 10
2,998 · median 210
Started
2019
with 1 other
No phase
6 of 10
1 open now
Registered
7th of 10
by date

Among the 10 studies in Melanoma by Melanoma and Skin Cancer Trials Limited, this one has the largest planned enrollment, is one of 2 that started in 2019, is one of 6 with no phase, and was the 7th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 10 studies in Melanoma by Melanoma and Skin Cancer Trials Limited are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Melanoma by Melanoma and Skin Cancer Trials Limited, or all of them as a file.
02

Study summary

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.

Read the detailed description

This study will determine whether there is a difference in disease-free survival rates for patients with primary cutaneous melanoma with Breslow thickness > 2mm or 1-2mm with ulceration (pT2b-pT4b, AJCC 8th edition), treated with either a 1cm excision margin or 2cm margin. The study is designed to be able to prove or disprove that there is no difference in risk of the tumour recurring around the scar or anywhere else in the body between the two groups of patients. If the study shows no risk of tumour recurrence then we will also be able to determine how much of an impact the narrower excision has on patients in terms of improved quality of life and reduced side effects from the surgery and melanoma disease. This trial will also evaluate and determine the economic impact of narrower excision margins on the health services and society in general.

03

Conditions studied

  • Cutaneous Melanoma, Stage II

Keywords

  • Malignant
  • Melanoma
  • Cancer
  • Surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be included in the study if they meet ALL of the following criteria:

    1. Patients must have a Stage II primary invasive cutaneous melanoma (pT2b-pT4b, AJCC 8th edition) with Breslow thickness >1.0mm to 2.0mm; >2.0mm to 4.0mm or >4.0mm with ulceration, or >2.0mm to 4.0mm; or >4.0mm without ulceration (Table 1) as determined by diagnostic (narrow excision, incision, shave or punch biopsy) and subsequent histopathological analysis.
  1. Must have a primary melanoma that is cutaneous (including head, neck, trunk, extremity, scalp, palm or sole).
  2. An uninterrupted 2cm margin must be technically feasible around biopsy scar or primary melanoma.
    1. Surgical intervention (which refers to the staging -SLNB and WLE as these are both to be done on the same day) must be completed within 120 days of the original diagnosis. Surgical intervention must also be performed within 28 days of randomisation.
  3. Patients must be 18 years or older at time of consent.
  4. Patient must be able to give and comply with the treatment protocol and follow up plan.
  5. of at least 5 years from the time of diagnosis, not considering the melanoma in question, as determined by the PI.
  6. Patients must have an performance score between 0 and 1 at screening.
  7. A survivor of prior cancer is eligible provided that ALL of the following criteria are met and documented:

    • The patient has undergone potentially curative therapy for all prior ,
    • There has been no evidence of recurrence of any prior malignancies for at least FIVE years (with the exception of successfully treated uterine/cervical or non-melanoma skin cancers (SCCs/BCCs) with no evidence of recurrence), and
    • The patient is deemed by their treating physician to be at low risk of recurrence from previous malignancies.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study for ANY of the following reasons:

  1. Uncertain diagnosis of melanoma i.e., so-called 'melanocytic lesion of unknown malignant potential'.
  2. Patient has already undergone WLE at the site of the primary index lesion.
  3. Patient unable or ineligible to undergo staging SLNB of the primary index lesion.
  4. Perineural invasion or neurotropic melanoma: Neurotropism or perineural invasion in any type of melanoma is an exclusion. Perineural invasion does not include entrapment of nerves within the main primary tumour mass.
  5. Desmoplastic melanoma: with any patient where pathology determines melanoma as PURE desmoplastic (as per WHO definition of >90% desmoplasia), they are not eligible for this study. However melanomas with less than 90% desmoplasia or mixed desmoplastic subtypes are eligible unless there is neurotropism present (perineural invasion).
  6. Microsatellitosis (a nest of tumour cells found to be growing away from the primary tumour) as per AJCC 8th edition definition is an exclusion.
  7. Subungual melanoma
  8. Patient has already undergone a local flap reconstruction of the defect after excision of the primary and determination of an accurate excision margin is impossible.
  9. History of previous or concurrent (i.e. >1 primary melanoma) invasive melanoma.
  10. Melanoma located distal to the metacarpophalangeal joint; on the tip of the nose; the eyelids or on the ear; genitalia, perineum or anus; mucous membranes or internal viscera.
  11. Physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional, or distant metastatic melanoma.
  12. Patient has undergone surgery on a separate occasion to clear the lymph nodes of the probable draining lymphatic field, including -SLNB, of the index melanoma.
  13. Any additional solid tumour or hematologic during the past 5 years (with exception of non- melanoma skin cancers (T1 skin lesions of squamous cell carcinoma (SCCs), basal cell carcinoma (BCCs)), or uterine/cervical cancer).
  14. Melanoma-related operative procedures not corresponding to criteria described in the protocol.
  15. Planned radiotherapy to the primary melanoma site after wide local excision is not permitted as part of the protocol and any patients given this treatment would be excluded from the study.
  16. History of organ transplantation.
  17. Oral or parenteral agents (not topical or inhaled ) at enrolment or within 6 months prior to enrolment.

Pregnancy is not a specific exclusion criterion for this trial, though it may not be clinically appropriate to perform a wide excision and SLNB until the pregnancy has been completed, which may exclude the patient due to violation of inclusion criterion 4. We would advise careful counselling of the patient prior to enrolling the patient, which would include a discussion at the treating centre's multidisciplinary team meeting or tumour board. We would strongly advise contacting the central trial office to discuss the case prior to enrolling on the study.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,998 participants (estimated)

Study arms

  • Experimental
    Arm A (Wide Local Excision = 1cm Margin)

    1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction

    Procedure: Wide Local Excision = 1cm Margin

  • Active comparator
    Arm B (Wide Local Excision = 2cm Margin)

    2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction

    Procedure: Wide Local Excision = 2cm Margin

Interventions

  • ProcedureWide Local Excision = 1cm Margin

    A wide local excision involves removing an extra "safety margin" of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed.

  • ProcedureWide Local Excision = 2cm Margin

    A wide local excision involves removing an extra "safety margin" of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed.

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival

    Time from randomisation until the first clinically, histologically or radiologically confirmed recurrence of melanoma at any body site, or death from any cause.

    Time frame: 0-60 months

Secondary outcomes

  1. Local Recurrence

    Time from randomisation to any clinically, histologically or radiologically confirmed LR of melanoma including satellite lesions and in transit metastases between the primary site and the regional draining lymph nodes or death from any cause.

    Time frame: Day 0-Trial Completion (max. 120 months)

  2. Distant Disease-Free Survival

    Time from randomisation to any clinically, histologically or radiologically confirmed distant recurrence of melanoma or death from any cause

    Time frame: Day 0-Trial Completion (max. 120 months)

  3. Melanoma-Specific Survival

    Time from randomisation to death due to melanoma

    Time frame: Day 0-Trial Completion (max. 120 months)

  4. Overall Survival

    Time from randomisation to death from any cause

    Time frame: Day 0-Trial Completion (max. 120 months)

  5. Melanoma-specific Quality of Life: FACT-M questionnaire

    Measured by FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire - It consists of two subsections: The FACT-G subsection is a 27-item compilation of general questions divided into four primary QOL domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. It is considered appropriate for use with patients with any form of cancer. The Melanoma Surgery Subscale evaluates melanoma-specific symptoms such as surgical morbidity and side effects.

    Time frame: Baseline, 3, 6, 12 & 24 months

  6. Neuropathic Pain: PainDetect questionnaire

    Measured by PainDetect questionnaire

    Time frame: Baseline, 3, 6, 12 & 24 months

  7. Health-related Quality of Life: EQ-5D-5L questionnaire

    Measured by EuroQoL EQ-5D-5L questionnaire - This tool contains 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

    Time frame: Baseline, 3, 6, 12 & 24 months

  8. Surgery Related Adverse Events

    The following surgical-related adverse events will be recorded from the time of surgery to 12-months following surgery (inclusive): * wound dehiscence * seroma/haematoma * haemorrhage * infection * skin graft failure * necrosis of flap used for reconstruction * deep venous thrombosis * urinary tract infection * pneumonia * cardiac complications * lymphoedema

    Time frame: Up to 12-months from the date of surgery

  9. Health Economic Evaluation

    Data collected for economic analysis will be from hospital notes, MBS and PBS data (Australia) and patient reported outcome measures (including an employment questionnaire) at baseline, 3, 6, 12 and 24 months and at melanoma recurrence.

    Time frame: Baseline, 3, 6, 12 & 24 months

  10. Serious Adverse Events

    All Serious Adverse events (SAEs), will be recorded from randomisation until 12 months post the surgical intervention or until the patient withdraws or dies.

    Time frame: from randomisation up to 12-months post-surgery

07

Study locations

185 of 192 sites recruiting

Showing the first 100 of 192 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Dec 2029, 120 months after the start.

Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 120 months is above that.

Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2019
First posted
Mar 4, 2019
StartActual
Dec 17, 2019
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2034
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03860883
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Collaborators
Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Responsible party
Sponsor
First posted
Mar 4, 2019
Start date
Dec 17, 2019
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Nov 27, 2024

Study contacts

Melanoma and Skin Cancer Trials Coordinator
Contact
melmart@masc.org.au
+61 3 9903 9022
Michael Henderson
study chair · Peter MacCallum Cancer Centre, Australia
Marc Moncrieff
study chair · Norfolk & Norwich University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion